{'fraction_non_alphanumeric': 0.016799292661361626, 'fraction_numerical': 0.009725906277630416, 'mean_word_length': 5.9447852760736195, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

Key Points Question Does targeting programmed cell death 1 or programmed cell death ligand 1 enhance the clinical benefits of anti–vascular endothelial growth factor therapy in patients with refractory metastatic colorectal cancer (mCRC)? Findings In this randomized clinical trial of 128 patients with refractory mCRC, the addition of atezolizumab to capecitabine and bevacizumab therapy led to marginally longer progression-free survival (PFS) compared with placebo (median, 4.4 months vs 3.6 months). Although this result met the prespecified threshold for statistical significance, the improvement in PFS was not clinically relevant. Meaning In this study, the addition of atezolizumab to capecitabine and bevacizumab therapy provided limited clinical benefit for patients with refractory mCRC, suggesting that cotargeting programmed cell death 1 or programmed cell death ligand 1 and vascular endothelial growth factor may not meaningfully improve PFS among a population with refractory mCRC.